Amino acid sequence microheterogeneities of a type I cytokeratin of Mr 51 000 from Xenopus laevis epidermis  by Hoffmann, Werner et al.
Volume 237, number 1,2, 178-182 FEB 06302 September 1988 
Amino acid sequence microheterogeneities of a type I cytokeratin 
of M, 51000 from Xenopus Zaevis epidermis 
Werner Hoffmann, Sylvia Sterrer and Andreas Kiinigstorfer 
Max-Planck-Institut ftir Psychiatric, Abteilung Neurochemie, Martinsried, FRG and Institut fir Molekularbiologie der 
dsterreichischen Akademie der Wissenschaften, Salzburg, Austria 
Received 27 July 1988 
The complete cDNA-derived sequence of a type I cytokeratin (designated no. 3) from Xenopus laevis skin is described. 
The deduced protein has an M, of 51888 and consists of a glycine-rich head domain, a well-conserved a-helical region 
and a tail rich in hydroxyamino acid residues. Various cDNA clones encoding two different mRNAs were isolated that 
differed by short deletions/insertions and point mutations. These microheterogeneities are mainly located in a ‘hypervari- 
able region’ at the C-terminal non-a-helical region. 
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1. INTRODUCTION 
Like desmin, vimentin, glial filament proteins 
and neurofilaments, the cytokeratins form one of 
the five major types of intermediate filaments (IF) 
with a diameter of 7-l 1 nm [ 11. This very complex 
family of keratin-type proteins is characteristic for 
epithelial cells and in human tissues 19 different 
polypeptides have been identified [2]. 
In Xenopus laevis the keratin pattern reveals 
drastic developmental changes during epidermal 
maturation [3]. However, in adult X. Iaevis epider- 
mis, a unique set of cytokeratins is synthesized 
ranging from M, 49 000 to 64 000 [4,5]. These poly- 
peptides can be divided into two different classes: 
type II molecules are basic with M, 64000 and are 
closely related to each other (designated nos la-c). 
On the other hand, acidic type I molecules are more 
diverse, and this class consists of at least three dif- 
ferent polypeptides with A4, of 53000 (no. 2), 
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The nucleotide sequence presented here has been submitted to 
the EMBL/GenBank database under the accession o. YOO968 
51000 (no. 3) and 49000 (no. 4). Using in vitro 
translation of hybrid-selected mRNAs, partial 
cDNA clones encoding cytokeratin nos la-c and 
cytokeratin no. 3 could be identified [6,7]. These 
cytokeratins (MI 64 000 and 51000) are not ex- 
pressed in oocytes, unfertilized eggs, liver or 
skeletal muscles of adult frogs [8]. During develop- 
ment, the mRNAs for the 64 kDa polypeptides 
first appear at stages 48-52, and that for the 
5 1 kDa protein before stage 46 [9]. Here we present 
the full-length sequence of the type I cytokeratin, 
with M, 51000 as deduced from cDNA cloning. 
2. MATERIALS AND METHODS 
All manipulations with DNA including cDNA cloning 
(pUF< 1000 clones) were performed as described [lo]. Addi- 
tionally, for the production of full-length clones, new improved 
cDNA libraries have been constructed (pUF> 1000 clones) as 
reported in [l I]. Screening of cDNA libraries with synthetic 
oligodeoxynucleotides has been described elsewhere [12] with 
the exception that Hybond-N membranes (Amersham) were 
used. DNA sequences were determined by a combination of 
both the Maxam-Gilbert protocol [13] using a modified G + A 
reaction [14] and the dideoxy method [15] after subcloning into 
different Ml3 vectors [16]. DNA sequencing data were com- 
puterized using programs purchased from Teufl-Software 
(Salzburg). A commercial program from the University of 
Wisconsin Genetics Computer Group (UWGCG, version 5.1) 
was used for the prediction of protein secondary structures. 
178 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/88/$3.50 0 1988 Federation of European Biochemical Societies 
Volume 237, number 1,2 FEBS LETTERS September 1988 
KERl KER2 pUF1371 m f 
130 TGGuAT6AATAm6CGGTGT~~ TAT666T66Cm66A6CTT6T66T6CA66CTATGGTMiT6G 
259 
3m 
517 
646 
775 
904 
1033 
1162 
1291 
1420 
1549 
1678 
T~T~T~T~~GT6GT~T~A~~T~~~~T~~CT~~~AT~T~T~~~T6~6T~TAT~GGT~~~Tffi~~~~ 
GGAG666AGYG66F666S6A6Y666F6G6Y666F666F6 
pUF451 
TGGTG6TGWXMAATG6ACATCllCTCTACCAA TMTGACCGCTT6GCmBTmTGCACT GGAGAUGUAATACT6AACl-r~ 
GGAGGMOIFSTNEKQTMDNLNDRLASYLDKVHALETANTELER 
pUF451_ 
CAA6AlWA6GAGTGGTA~CA6G6AGfXMTG&WT 6666uAAGMcTAcTcuMTAnATAcTAT~A~~MT~CT~T~~~~~~T~ 
KIKEWYEKQRP6SSS6DGAKOYSKYYTHINOLKNQIIAASIEN 
T 
451 
PstI 
A451 
T6CAAAAlTTCTTCTGu6AA~T6C~6cTGATGACmAAMTGAAATllGAMAT~TACA T6C66CAGAUGT66A66CTSATATCAATG6TCTGCGTAGAGTCAT66A 
AKFLLQNDNARKLAADDFKMKFENEQYHRQTVEADINGLRRVHD 
SphI 
A4s1 
lGATCT-MCCCTGTCCAAGTCT6WT66AATCTCAGClXMGTC~ CCTATCTTMGMGMfCATGMGACGAACTTMA66CATGUKiT 
DLTLSKSDLESQLESLSEELAYLKKNHEDELK6HQYTQVGQVN 
BglII 
TGTA6AAAT64ATGCTGCACCMGlXTGAC TXACCAMTACTCAATGATATGAGWTMT ATtMG4TCTAGCCTGCAGCAGMAGGAAWTKMCAWAT6AGTACT6A 
VEklNAAPSSDLTKILNOHRSQYEDLAKRNRAAAEEQFNRHSTD 
CCfGMMATAUICmT~~~T~~TC~T~~~~T~~~TCTCT 
LKNTLSQ6IEQQKESKSELTELKRTLQSLEI'ELQSQLA~KKSL 
PstI 
GGA6ATWXCT6GCT l?TCTGTATGAWTGT6AGCA6ATAGCACGACTCAMGGAW TCAGAGT6CCAQ'CCTA 
EMTLAEVEGSFCHKLSRLDEHIVNVEEQIARLK6ESECDTAEY 
BglII (A 1 1 CTG6CCCACCCAGGC 
A _)451 
CCAAWCTCllGGACATCM64CMG GCTGWMT64MTT6WCATATCGCA6GCTCCTG6AT66A6ATCTGMMMCCA~ -AMGTGGTS6AGGCACCACTACTMTAC 
QQLLDIKTRLENEIETYR R LLD6DL,,SIK PSTGppK KoS 666 TSTT,NT 
pUFlOO1 
AGGTTCTACAT~CMC~~TTA~GT66T GTCAWAMTCGTA6ATATGTAMAGM6GT6CAGWMGT6CA 
6STSSK6STRTVKRREIIEEVVO6KVVSTKVVDbl 
'451 c451 
CGCTlGTTACTACTATAMGCTTATTMMl~TGTCAMC CTTMTCTGCTTGTAGCUTACTTATA~C~~T~~A~~~~~~TAT~~~ 
A4s1 
CACAATAAACA~CTGAT6CAAGCTAT~ly(A) 
Fig.1. Nucleotide sequence and deduced amino acid sequence of XLSl. The full-length sequence was obtained from cDNA clones 
pUF1371, pUFlOO1 and pUF454. In the line above, the differences observed in cDNA clone pUF451 are displayed, when compared with 
the combined full-length sequence. Asterisks were introduced to maximize homology (introducing gaps into the sequences). Restriction 
sites, the polyadenylation signal AATAAA, and the positions of the synthetic oligonucleotides KERl and KER2 are underlined. The 
lower line of the amino acid sequence represents the differences observed in pUF451 when compared with the full-length sequence 
deduced from pUF1371, pUFlOO1 and pUF454. 
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3. RESULTS 
Starting with the BglII-EcoRI fragment of 
cDNA clone pUF29 [7], which encodes only a C- 
terminal portion of the type I cytokeratin with M, 
51000 (designated no. 3), we screened the original 
library of X. luevis skin [lo] for longer clones and 
obtained pUF451 and pUF454 (fig. 1). Subsequent- 
ly, the smallest PHI fragment of pUF451 (cor- 
responding to the most 5 ‘-sequences obtained so 
far) was used as the next hybridization probe for an 
improved library resulting in the isolation of clone 
pUF1001. In order to obtain the 5’-end of the 
mRNA cloned, a different approach was applied: 
based on the 5 ‘-sequence of clone pUFlOO1 the 
oligonucleotides KERl d(AATATTCATTTCCA- 
CC) and KER2 d(GCCTCCTACACCGCAAAA) 
were constructed. KER2 was used as a primer to 
produce a partially enriched cDNA library of X. 
laevis skin, which was screened with KERl. Of 
about 500 clones, a single positive designated 
pUF1371 could be picked. 
4. DISCUSSION 
4.1. Nucleic acid sequence 
Fig.1 represents the combined full length se- 
quence of a type I cytokeratin (XL51) as deduced 
from cDNA-clones pUF1371, pUFlOO1 and 
pUF454. The overlapping sequences of all three 
clones are identical (40 and 787 nucleotides, respec- 
tively). This combined sequence differs in a few 
point mutations and deletions/insertions from the 
sequence derived from the insert of pUF45 1. Both 
new sequences presented here also differ from the 
previously published sequence of pUF29 [7]. These 
differences are exclusively located at the extreme 
3 ‘-non-coding-region. Due to processing errors, 
the sequence of pUF29 [7] had to be corrected at 
four different positions (position 42, C to G; 292, 
A to G; 507, T to C, and insertion of T after 596 ac- 
cording to the numbering in [7]. 
The microheterogeneities observed probably 
arise from the quasi-tetrapolid genome of X. laevis 
[17] resulting from a duplication of the genome 
about 30 million years ago [ 181. This long time 
period could easily account for the evolutionary 
drift of these two sets of genes. Similar 
microheterogeneities have previously been reported 
repeatedly, e.g. for vitellogenin [ 191. 
The ldngth of the full sequence presented here 
(1692 nucleotides without the poly(A) tail) fits very 
well with the result from the Northern analysis 
showing a band of about 1.8 kilobases [7]. The 
deduced full-length amino acid sequence (derived 
from pUF1371, pUFlOO1 and pUF454) results in 
Fig.2. Comparison of XL51 (see fig. 1) with cytokeratin XK81 present in gastrulae of X. Iuevis [26] and human type I cytokeratin HSOK 
[21,25]. Asterisks were introduced to maximize homology (introducing gaps into the sequences) and bars in XK81 and H50K represent 
identical amino acid residues when compared with XL51. Also shown are the predicted cu-helical regions (lA, lB1, lB2,2A, 2B, 3) ac- 
cording to Garnier et al. [24]. Black triangles identify positions of the seven introns as determined for H50K [25]. 
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an M, of 5 1888 including the initiating methionine, 
which is most likely lost in the mature protein. This 
is in very good agreement with the Mr determined 
by gel electrophoresis, which is 51000 [7]. The 
3 ‘-non-coding-region of the mRNA presented in 
fig.1 comprises 185 nucleotides not including the 
poly(A) tail. This is considerably shorter than that 
of an mRNA encoding a type II cytokeratin of X. 
laevis epidermis (iMr 64000), which consists of an 
3 ‘-untranslated region of 476 nucleotides [20]. A 
similar result has been reported for human 
cytokeratins [21,22]. 
Remarkable is the high similarity of about 28 
bases at the extreme 3 ‘-ends of the mRNA en- 
coding a type I cytokeratin (Mr 59000) of mouse 
[23] and of the sequence presented in fig.1. 
4.2. Secondary structure 
A secondary structure prediction according to 
Garnier et al. [24] revealed three major domains 
(see fig.2). The glycine-rich head domain at the N- 
terminal has mainly &turn structure and in the 
middle of the molecule a cluster of helical regions 
can be distinguished (coils lA, lB1, lB2, 2A, 2B). 
The tail is rich in hydroxyamino acid residues also 
indicating &turns, and a short a-helical region 
(coil 3) can be predicted only at the extreme C- 
terminal. 
Nearly all microheterogeneities occur within the 
C-terminal tail region. The large insertion of 15 
nucleotides in pUF451 mainly affects the position 
of proline residues, marking the end of coil 2B. 
This hypervariable region is located just at the end 
of the coiled-coil structure, similarly to that 
previously described for various basic cytokeratins 
of X. laevis [6]. Based on the homology with 
human 50 kDa cytokeratin [21,25] (see fig.2), this 
hypervariable region would be entirely located 
within exon 7. 
4.3. Homologies 
As illustrated in fig.2, the sequence presented 
here (XL51) shows strong homology with other 
type I cytokeratins from frog (XK81) and man 
(H50K), which is no. 14 according to the catalog of 
human cytokeratins [2]. Clearly, the highest degree 
of homology is concentrated within the a-helical 
rod domain in the middle. The non-a-helical head 
and tail regions of the molecules show only the 
well-conserved potential to form &turns. At the 
extreme C-terminal end there is again a short but 
highly conserved stretch of about 11 amino acid 
residues, which can form an a-helical structure 
(coil 3). 
The sequence comparison in fig.2 also displays 
clearly that XK8 1, present mainly during gastrula- 
tion but also present in a few organs of adult X. 
faevis (Franke, W. W., personal communication), 
shares more similarity with human cytokeratin no. 
14 in the a-helical domain than does XL51. Con- 
versely, the human sequence is closer to XL5 1 than 
XK81 with respect to the length of the non-a- 
helical head and tail domains, accounting for the 
very similar molecular masses of HSOK and XL5 1. 
In contrast to all other type I cytokeratins se- 
quenced,. the non-a-helical head domain of XL5 1 
contains three acidic residues at positions 30, 38 
and 40 (see fig.2). Typically, this domain contains 
a few basic residues. 
In conclusion, we believe that the type I 
cytokeratin (Mr 51000) presented here is probably 
not the direct amphibian counterpart of human 
cytokeratin no. 14, despite their very similar M, 
values. It might, however, be the equivalent of no. 
13 (Mr 54 000) or the more acidic no. 15 (Mr 50 000) 
of the human catalog [2]. 
Acknowledgements: We thank Eva-Maria Gertzen (Martin- 
sried) for valuable technical assistance and U. Schimanko and 
D. Weigand (Martinsried) for quick support with synthetic 
oligonucleotides. We are also indebted to Dr P. Kiister (Martin- 
sried) for help in handling the computer and Dr D. Edgar (Mar- 
tinsried) for critical reading of the manuscript. Part of this pro- 
ject was supported by a grant from the Bundesministerium fur 
Wissenschaft und Forschung (Austria). 
REFERENCES 
[1] Steinert, P.M. (1985) Annu. Rev. Cell Biol. 1, 41-65. 
[2] Moll, R., Franke, W.W., Schiller, D.L., Geiger, B. and 
Krepler, R. (1982) Cell 31, 11-24. 
[3] Ellison, T.R., Mathisen, P.M. and Miller, L. (1985) Dev. 
Biol. 112, 329-337. 
[4] Franz, J.K., Gall, L., Williams, M.A., Picheral, B. and 
Franke, W.W. (1983) Proc. Natl. Acad. Sci. USA 80, 
6254-6258. 
[5] Franz, J.K. (1982) Diploma Thesis, Faculty of Biology, 
University of Heidelberg, pp. l-l 10. 
[6] Hoffmann, W., Franz, J.K. and Franke, W.W. (1985) J. 
Mol. Biol. 184, 713-724. 
[7] Hoffmann, W. and Franz, J.K. (1984) EMBO J. 3, 
1301-1306. 
[8] Franz, J.K. and Franke, W.W. (1986) Proc. Natl. Acad. 
Sci. USA 83, 6475-6479. 
181 
Volume 237, number 1,2 FEBS LETTERS September 1988 
[9] Mathisen, P.M. and Miller, L. (1987) Genes Devel. 1, [18] Thiebaud, C.H. and Fischberg, M. (1977) Chromosoma 
1107-1117. 59, 253-257. 
[IO] Hoffmann, W., Bach, T.C., Seliger, H. and Kreil, G. 
(1983) EMBO J. 2, 111-114. 
[ll] Hoffmann, W. (1988) J. Biol. Chem. 263, 7686-7690. 
[12] Singer-Sam, J., Simmer, R.L., Keith, D.H., Shively, L., 
Teplitz, M., Itakura, K., Gartler, S.M. and Riggs, A.D. 
(1983) Proc. Natl. Acad. Sci. USA 80, 802-806. 
[13] Maxam, A.M. and Gilbert, W. (1980) Methods Enzymol. 
65,499-560. 
[19] Waltli, W. and Dawid, I.B. (1979) Cell 16, 535-549. 
[20] Konigstorfer, A. (1987) Master Thesis, Faculty of Science, 
University of Salzburg, pp. l-25. 
[21] Hanukoglu, I. and Fuchs, E. (1982) Cell 31, 243-252. 
[22] Hanukoglu, I. and Fuchs, E. (1983) Cell 33, 915-924. 
[23] Krieg, T.M., Schafer, M.P., Cheng, C.K., Filpula, ‘D., 
Flaherty, P., Steinert, P. and Roop, D.R. (1985) J. Biol. 
Chem. 260, 5867-5870. 
[14] Cooke, N.E., Coit, D., Shine, J., Baxter, J.D. and 
Martial, J.A. (1981) J. Biol. Chem. 256, 4007-4016. 
[15] Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. 
Natl. Acad. Sci. USA 74, 5463-5467. 
[16] Messing, J. (1983) Methods Enzymol. 101, 20-78. 
[17] Bisbee, C.A., Baker, M.A., Wilson, A.C., Azimi, I.H. 
and Fischberg, M. (1977) Science 195, 785-787. 
[24] Garnier, J., Osguthorpe, D.J. and Robson, B. (1978) J. 
Mol. Biol. 120, 97-120. 
[25] Marchuk, D., McCrohon, S. and Fuchs, E. (1985) Proc. 
Natl. Acad. Sci. USA 82, 1609-1613. 
[26] Jonas, E., Sargent, T.D. and Dawid, I.B. (1985) Proc. 
Natl. Acad. Sci. USA 82, 5413-5417. 
182 
